Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Line Bisgaard Jørgensen, Lars Bastholt, Knud Bonnet Yderstræde

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.
Original languageDanish
Article numberV05170362
JournalUgeskrift for Læger
Volume179
Issue number2
Pages (from-to)132-136
ISSN0041-5782
Publication statusPublished - 1. Jan 2018

Cite this